Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-070994

Chief Executive Officer acquired 17,750 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2021-12-20 Option exercise +17,750 $1.81 $32,128 279,085 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2021-12-20 Option exercise · Stock Option (Right to Buy) −17,750 58,233 D
Loading xslF345X03/doc4.xml…